Answer

Introduction

Regulatory flexibility in the pharmaceutical sector must not come at the cost of public health safeguards. While “Ease of Doing Business” is vital for India’s ₹3.4 lakh crore industry, the “Pharmacy of the World” title risks erosion if relaxations by the Central Drugs Standard Control Organization (CDSCO) lead to a “conditional ease” that compromises drug quality and efficacy.

Body

CDSCO Relaxations and the Quest for Flexibility

• Compounding of Offences: The Drugs and Cosmetics (Compounding of Offences) Rules, 2025 allow firms to settle minor non-compliance through fines instead of criminal prosecution. 
• Abbreviated Clinical Trials: CDSCO has allowed the relaxation or deferment of non-clinical and clinical data for drugs targeting life-threatening or rare diseases and unmet Indian needs.
• Digital Transformation (Go-SUGAM): Transitioning to the SUGAM online portal for post-approval changes in clinical trials  speeds up the regulatory lifecycle.
• Deemed Approval Provision: If the Central Licensing Authority does not communicate within 90 days for certain BA/BE study applications, permission is now “deemed” granted. 
• Self-Regulation in Marketing: The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2025 relies on industry associations to protect data and self-regulate sample distributions. 
• Revised Risk Classification: New provisions for Risk Classification of Medical Devices on the CDSCO online system aim to streamline the licensing of low-risk devices. 
• Flexible Similar Biologics: The Draft Guidelines on Similar Biologics (2025) facilitate a stepwise approach to demonstrate “similarity,” reducing the burden of repetitive trials. 
• Decriminalizing Minor Lapses: By distinguishing between “not of standard quality” (NSQ) and “spurious” drugs, the regulator avoids treating minor technical errors as criminal acts. 

Conclusion

The path forward lies in a “Zero-Threshold Policy” for poor quality. While compounding minor offences is efficient, it must be accompanied by mandatory “Risk-Based Inspections” and a robust “Adverse Drug Reaction” reporting system through QR codes at pharmacies. Regulatory flexibility should empower innovation but must never bypass the “hawk-like monitoring” necessary to prevent tragedies like contaminated cough syrups, ensuring Indian medicines remain both affordable and safe.

DOWNLOAD PDF